Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abuse Liability of IV NRP104 in Stimulant Abusers
NCT00247572Phase 2Completed
- Sponsor
- New River Pharmaceuticals
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD) (4 arms), sponsored by New River Pharmaceuticals. Primary endpoints: Maximum liking scale scores for euphoria, Maximum disliking scale scores for dysphoria and 8 more. Started Sep 2005; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00247572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00247572.